NeuroSense Therapeutics is a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
The objective of this trial was to evaluate the safety of their treatment, with a secondary objective of the trial of estimating its preliminary efficacy.
The median overall survival for all CENTAUR study participants being administered AMX0035 was 6.5 months longer than the group originally randomized to placebo.
"We are now focused on advancing strategic FDA regulatory processes that will necessitate the conduct of global multi-center clinical trials."
AstroRx is a cell therapy product containing functional healthy astrocytes derived from human embryonic stem cells that aim to protect diseased motor neurons.
Rabbi Yitzi Hurwitz, 47, writes a weekly commentary on the Torah and a blog offering marriage advice.
"Some people enjoy insulting Paolo," said his brother to local media. "They look for any way to sabotage his actions."
Dina was driving the older children from school in LA on a Friday when Yitzi phoned with the dread diagnosis. It was his 41st birthday.
There is currently neither a cure nor an effective treatment to halt or reverse the progressive disease.
NeuroSense is planning to commence clinical trials later this year in the United States and Israel.